Price
$35.23-13.76%Social Signal Score
Analyst Ratings
17 analystsRevenue
$7.68B+24.25%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James Boyle
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 45,000
- Beta
- -0.41
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.07
Financials
MDLN has only 8 quarterly periods on file — the charts below show the full history available.
Revenue
$7.68B+24.3%Net Income
$60.00M-79.5%EBITDA
$659.00M-18.2%Free Cash Flow
$604.00M-1.8%EPS (diluted)
$0.07-81.1%Shares Outstanding (diluted)
861.00M+9.4%Operating Expenses
$1.29BCash & Debt
$2.68BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $28.43B | $1.16B | $1.43 |
| 2024 | $25.51B | $1.20B | $1.52 |
| 2023 | $23.23B | $234.00M | $0.30 |
| 2022 | $21.45B | $-25.00M | $-0.03 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.10
- Implied price
- $60.82
- Return from $35.61
- 11.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.24 — -15.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | -5.3% | -2.0% | 1.0% | 3.6% | 6.0% |
| 3.0% | -0.5% | 3.0% | 6.1% | 8.9% | 11.4% |
| 8.0% | 4.3% | 8.0% | 11.3% | 14.2% | 16.9% |
| 13.0% | 9.2% | 13.0% | 16.5% | 19.5% | 22.3% |
| 18.0% | 14.0% | 18.0% | 21.6% | 24.8% | 27.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-37.50%Social Signal Score
Mentions (8)
- Newsprnewswire.com·4h ago·Negative
MDLN Stock Notice: Medline Stock Plummeted 13% after Product Quality Issues Disclosed - Securities Fraud Investigation Underway BFA Law is investigating whether Medline Inc. committed securities fraud relating to statements about Medline's manufacturing and product quality. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ: MDLN) for potential securities fraud after its significant stock drops.
View source ↗ - Newsglobenewswire.com·1d ago·Negative
MDLN Investigation Notification: Medline is Under Investigation for Securities Fraud over Product Quality Issues – Contact BFA Law if You Suffered Losses NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfala…
View source ↗ - Newsglobenewswire.com·11d ago·Negative
MDLN Stock Drop Alert: Medline Stock Plummets 13% after Product Quality Issues Revealed – BFA Law Notifies Investors of its Ongoing Securities Fraud Investigation NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
$MDLN Stock Notification: Medline Inc. is Being Investigated for Securities Fraud after Product Quality Issues Disclosed – Investors are Alerted to Contact BFA Law NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops.
View source ↗ - Newsbusinesswire.com·13d ago·Negative
MDLN Stock Drop Alert: Medline Inc.'s Stock Drops 13% over Product Quality Issues Triggering Securities Fraud Investigation by BFA Law NEW YORK--(BUSINESS WIRE)---- $MDLN #BFA--Medline Inc.'s Stock Drops 13% over Product Quality Issues Triggering Securities Fraud Investigation by BFA Law.
View source ↗ - News (RSS)businessinsider·19d ago·Negative
Kaplan Fox Alerts Investors of Medline Inc. (MDLN) to a Securities Law Investigation <img src="https://api.newsfilecorp.com/newsinfo/314588/208" id="208" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;">New York, New York--(Newsfile Corp. - September 16, 2026) - <a href="https://api.newsfilecorp.com/redirect/Gz3EbTWR1P" rel="noopener nofollow" target="_blank">Kaplan Fox Kilsheimer LLP</a> is...
View source ↗ - News (RSS)businessinsider·49d ago·Negative
Kaplan Fox & Kilsheimer LLP is Investigating Medline Inc. (MDLN) for Possible Securities Law Violations <img src="https://api.newsfilecorp.com/newsinfo/309916/208" id="208" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;">New York, New York--(Newsfile Corp. - August 17, 2026) - <a href="https://api.newsfilecorp.com/redirect/RYmYGfwX2x" rel="noopener nofollow" target="_blank">Kaplan Fox Kilsheimer LLP</a> is investigating...
View source ↗ - News (RSS)businessinsider·52d ago·Negative
Kaplan Fox Reminds Medline Inc. (MDLN) Investors of an Investigation into Potential Securities Law Violations <img src="https://api.newsfilecorp.com/newsinfo/309091/208" id="208" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;">New York, New York--(Newsfile Corp. - August 14, 2026) - <a href="https://api.newsfilecorp.com/redirect/wELgrSrGbK" rel="noopener nofollow" target="_blank">Kaplan Fox Kilsheimer LLP</a> is investigating...
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.34 per share
Typical surprise +11.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.50 vs $0.35beat
- Wed, May 6$0.33 vs $0.30beat
- Wed, Feb 25$0.22 vs $0.24miss
Estimates and results for MDLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDLN officers and directors.
- Bought
- —
- Sold
- $4.4bn
0 trades
12 trades
- Bcp 8 Holdings Mozart Manager L.l.c.sold
- Bcp 8 Holdings Mozart Manager L.l.c.sold
- Bcp 8 Holdings Mozart Manager L.l.c.sold
- Bcp 8 Holdings Mozart Manager L.l.c.sold
- Carlyle Group Inc.sold
- Bcp 8 Holdings Mozart Manager L.l.c.sold
- Bcp 8 Holdings Mozart Manager L.l.c.sold
- Bcp 8 Holdings Mozart Manager L.l.c.sold
43 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MDLN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.